Recent 8-K filings for ANGO

• April 2, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance

  Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.

• February 3, 2026, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 9.01

  CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs

  Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.

• January 6, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%

  Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.

• October 2, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance

  Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.

• July 15, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 7.01item 9.01

  AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%

  Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.

• April 2, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY

  Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.

• January 8, 2025, 6:59 PM ET earnings materiality 0.78 positive item 2.02item 7.01item 9.01

  AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M

  Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).

• October 3, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11

  Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).

• July 16, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment

  Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.

• July 16, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 7.01item 9.01

  AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M

  Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.

• April 4, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  AngioDynamics Q3 pro forma sales up 8%; GAAP loss $4.73/sh on $159.5M goodwill impairment; guidance cut

  Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.

• April 1, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 ◈ Material Agreements

  AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums

  One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event earnings

6 positive 2 negative 12 neutral

source · ANGO on sec.gov